Charles River Laboratories International Inc 's Revenue in the fiscal year 2025 $ 4,015.38 millions
Charles River Laboratories International Inc 's Revenue in the fiscal year 2024 $ 4,049.99 millions
Charles River Laboratories International Inc 's Revenue in the fiscal year 2023 $ 4,129.41 millions
Charles River Laboratories International Inc 's Revenue in the fiscal year 2022 $ 3,976.06 millions
Charles River Laboratories International Inc 's Revenue in the fiscal year 2021 $ 3,540.16 millions
CRL Revenue third quarter 2026 Y/Y Growth Comment
Charles River Laboratories International Inc reported decrease in Revenue in the third quarter 2026 by -2.2% to $ 982.73 millions, from the same quarter in 2025. The decrease in the third quarter 2026 Charles River Laboratories International Inc 's Revenue compares unfavorably to the Company's average Revenue growth of 8.13%.
Looking into third quarter 2026 results within Medical Laboratories industry 26 other companies have achieved higher Revenue growth. While Charles River Laboratories International Inc ' s Revenue decline of -2.2% ranks overall at the positon no. 3050 in the third quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Charles River Laboratories International Inc 's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
22.31 %
1.96 %
-6.41 %
(Jun 25 2016)
CRL's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Charles River Laboratories International Inc disclosed fall in Revenue from the second quarter by -2.13% to $ 982.73 millions, from $ 1,004.08 millions achived in the previous reporting period.
But that's not important problem, as Charles River Laboratories International Inc 's Revenue generally seem to plunge in this quarter.
Within Medical Laboratories industry 11 other companies have achieved higher Revenue quarter on quarter growth. While Charles River Laboratories International Inc 's Revenue growth quarter on quarter, overall rank is 1631.
In the III. Quarter 2026 Charles River Laboratories International Inc disclosed fall in Revenue from the second quarter by -2.13% to $ 982.73 millions, from $ 1,004.08 millions achived in the previous reporting period.
But that's not important problem, as Charles River Laboratories International Inc 's Revenue generally seem to plunge in this quarter.
Within Medical Laboratories industry 11 other companies have achieved higher Revenue quarter on quarter growth. While Charles River Laboratories International Inc 's Revenue growth quarter on quarter, overall rank is 1631.
Charles River Laboratories International Inc 's 12 Months Revenue Growth Year on Year
For the 12 months ended Jun 27 2026 Charles River Laboratories International Inc reported a decrease in Revenue by -0.74% year on year, to $3,999 millions, compare to the 0.11% growth at Mar 28 2026.
In the Healthcare sector 384 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2263 to 2691.
For the 12 months ended Jun 27 2026 Charles River Laboratories International Inc reported a decrease in Revenue by -0.74% year on year, to $3,999 millions, compare to the 0.11% growth at Mar 28 2026.
In the Healthcare sector 384 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2263 to 2691.
About Charles River Laboratories International Inc Revenue Growth Rates (CRL), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
What’s included here
Company: Charles River Laboratories International Inc
(CIK 1100682).
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.